Although biosimilars are consistently gaining more traction in Europe, they still face a number of significant challenges before they can take off in the U.S.
Dr. Roy Fleischmann tells Specialty Pharmacy Times that biosimilars currently offer little, if any, savings, and thus present no cost benefit to the patient.
“The whole rationale behind biosimilars is that they would be as effective, as safe, and considerably cheaper than the reference product,” Fleischmann says. “For my patients in the United States, there are no savings from biosimilars.
“The savings, if there are any, go exclusively to pharmacy benefit managers and vertically integrated healthcare systems,” he added.